Literature DB >> 27235612

Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.

Alison M Bays1, Gregory Gardner2.   

Abstract

Disease-modifying antirheumatic drugs (DMARDs) are commonly prescribed by rheumatologists to reduce disease activity and induce remission in autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis. Steroids are sometimes used in combination with DMARD therapy and should be used at the lowest effective dose for the least amount of time. There are many biologic agents available for use for inflammatory arthritis and other autoimmune conditions. Care should be taken when prescribing and managing DMARDS, steroids and biologic agents medications with a careful eye towards screening for infectious disease, vaccination, bone heath and lab monitoring.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune; Biologic agents; Disease-modifying antirheumatic drugs (DMARDs); Gout; Immunosuppression; Rheumatology

Mesh:

Substances:

Year:  2016        PMID: 27235612     DOI: 10.1016/j.mcna.2016.03.001

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  5 in total

1.  Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.

Authors:  Catherine Schairer; Ruth M Pfeiffer; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-24       Impact factor: 7.396

2.  Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis.

Authors:  Erika Darrah; AeRyon Kim; Xi Zhang; Tatiana Boronina; Robert N Cole; Andrea Fava; Jon T Giles; Clifton O Bingham III; Michael J Chalmers; Patrick R Griffin; Scheherazade Sadegh-Nasseri; Antony Rosen
Journal:  J Proteome Res       Date:  2016-10-20       Impact factor: 4.466

Review 3.  Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.

Authors:  Jun Liu; Hui Zhang; Yanhong Su; Baojun Zhang
Journal:  Cell Biosci       Date:  2022-05-26       Impact factor: 9.584

4.  Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution.

Authors:  Kristina Laugesen; Henrik Støvring; Jesper Hallas; Anton Pottegård; Jens Otto Lunde Jørgensen; Henrik Toft Sørensen; Irene Petersen
Journal:  Clin Epidemiol       Date:  2017-11-16       Impact factor: 4.790

Review 5.  Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation.

Authors:  Inmaculada Serrano; Ana Luque; Josep M Aran
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.